Michael Feld, Executive Vice President and Chief Revenue Officer at Becton Dickinson & Co (NYSE:BDX), sold 75 shares of common stock on March 26, 2026, at a price of $156.83, for a total transaction value of $11762.
Following the transaction, Feld directly owns 21,233 shares of Becton Dickinson & Co. The sale was executed under a Rule 10b5-1 trading plan adopted on February 7, 2025.
In other recent news, Becton Dickinson reported fiscal first-quarter 2026 results that surpassed consensus expectations, with ex-foreign exchange revenue growth of 0.4% year-over-year. This performance exceeded the company’s guidance of low-single-digit declines. Additionally, Becton Dickinson has initiated tender offers to purchase up to $1.6 billion of its outstanding debt securities, covering 15 different series with varying maturity dates. The company also received FDA clearance for its Surgiphor 1000mL antimicrobial irrigation system, designed to aid in surgical procedures by removing debris and microorganisms from wounds.
In terms of analyst activity, RBC Capital lowered its price target for Becton Dickinson to $172 from $210, maintaining a Sector Perform rating. Meanwhile, Argus reduced its price target to $180 from $230 but continued to support a Buy rating, citing market turbulence as a factor. These developments highlight the company’s strategic focus on growth opportunities in the Medical and Interventional segments. Raymond James noted that Med Tech pricing has remained largely flat in 2025, following a brief positive trend in previous years.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for BDX plus thousands of other stocks and find your next hidden gem with massive upside.